TriSalus Life Sciences (TLSI) to Release Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is set to post its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect TriSalus Life Sciences to post earnings of ($0.37) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $7.36 million for the quarter. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Stock Performance

TLSI opened at $4.16 on Thursday. The stock has a market capitalization of $121.93 million, a PE ratio of -1.66 and a beta of 0.49. The stock’s 50 day moving average price is $4.46 and its 200-day moving average price is $6.05. TriSalus Life Sciences has a 52-week low of $3.32 and a 52-week high of $10.42.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Northland Securities initiated coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Finally, Oppenheimer started coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $12.50.

Insider Buying and Selling at TriSalus Life Sciences

In related news, CEO Mary T. Szela bought 7,520 shares of the stock in a transaction on Thursday, September 12th. The shares were acquired at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 32.80% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.